Justin A. Boyd
Consumer Safety Officer
ORA Team Biologics / CDER-OC-OMQ International Operations (Madison, WI)
One of the FDA's most prolific international investigators — 33 483s across 26 countries with a focus on contamination control, environmental monitoring, data integrity, and computerised system audit trails. Recognised for detecting systemic data manipulation at Intas Pharmaceuticals.
Inspection Approach
How Justin Inspects
Boyd conducts exhaustive, multi-week inspections that combine direct observation of live operations with deep-dive documentation reviews. He physically observes aseptic filling lines, checking whether documentation timestamps match real-time activity — at Apotex, he caught an operator entering a 3:45pm sampling time at 4:19pm. He routinely pulls aggregate environmental monitoring data over extended periods rather than reviewing individual results, expecting firms to trend and act on cumulative signals.
A signature pattern is his focus on computerised system controls. Boyd systematically audits every electronic system in a facility — HMI panels, filling machines, particle counters, integrity testers, sterilisers — checking for shared credentials, missing audit trails, and the ability to overwrite failed test results. At Apotex alone, he identified six systems with inadequate 21 CFR Part 11 controls.
He is also known for scrutinising investigation depth and expansion. When a batch fails or a complaint is received, Boyd checks whether the investigation was extended to other products, lots, and time periods. At Intas, he flagged that a wrong-strength vial complaint investigation was not expanded to other lots — a finding that escalated to a warning letter and import alert after his team uncovered systematic data manipulation across multiple operators.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
Apotex Inc.
- Shared usernames/passwords on aseptic filling HMI with no audit trail on filling machine
- Approximately 404 elevated access requests in 2 years without documentation of justification
- Environmental monitoring not documented contemporaneously — operator entering 3:45pm sampling time at 4:19pm
- No hold time studies for bulk solution bags before filling; no stability data for held batches
- Leak test software allows overwriting failed tests without audit trail
Sun Pharmaceutical Industries Ltd.
- Since January 2024: 3 batch rejections from EM excursions, 30 Grade A recoveries, 76 Grade B action level results on one line
- EM excursion investigations failed to identify root causes for Gram-negative, spore-forming, and mold organisms
- Personnel movement issues in Grade A areas with unexplained process timing discrepancies
Pharmathen International S.A.
- Settle plates in Grade A area not positioned in accordance with procedure during aseptic filling
- EM programme did not include sampling of product-contact surfaces: stopper bowl, stopper track, forceps
- EM plates did not include neutralisers despite spray disinfectants being routinely used in Grade A and B areas
Intas Pharmaceuticals Limited
- Wrong-strength vial complaint investigation not expanded to review other lots or products
- No recall decision made within required timeline after confirmed mix-up
- Follow-up inspection (May 2023) uncovered manipulated visual inspection reports — rejection rates altered to avoid deviations
- FDA described "egregious pattern" of data manipulation involving multiple staff
Fareva Amboise
- Aseptic processing and sterilisation control deficiencies
- Environmental monitoring programme gaps in classified areas
Baxter Oncology GmbH
- Contamination control deficiencies in sterile manufacturing
- Environmental monitoring and aseptic processing observations
Pre-Inspection Preparation
How to Prepare
- 1 Audit every computerised system for 21 CFR Part 11 compliance — Boyd checks HMI panels, filling machines, particle counters, integrity testers, and sterilisers for shared credentials, missing audit trails, and ability to overwrite results.
- 2 Verify all documentation timestamps match real-time activity. Boyd physically observes operations and cross-references LIMS entry timestamps against actual sample collection times.
- 3 Pull your own aggregate EM trending data for the past 12+ months. Boyd does not review individual results — he requests cumulative data and expects firms to demonstrate they are trending and acting on it.
- 4 Ensure OOS/OOT investigations extend beyond the immediate batch to other products, lots, and time periods. Incomplete investigation expansion is a hallmark Boyd finding.
- 5 Document hold time studies for bulk solutions with scientific data — not just media fills. Boyd expects chemical stability, sampling timepoints, and packaging integrity evidence.
- 6 Review elevated access request logs for computerised systems. Boyd cited ~404 undocumented elevated access requests at one facility.
- 7 Verify cleaning validation adequately covers worst-case scenarios and that swab analytical methods have no co-elution issues with active/degradant peaks.
- 8 Prepare data integrity documentation showing no capacity to overwrite, delete, or alter electronic records without a permanent audit trail.
- 9 Ensure all personnel in Grade A areas can explain process timing and movements — Boyd will question operators directly about their activities.
- 10 If you have received a prior 483 or warning letter, document comprehensive corrective actions with objective evidence of sustained effectiveness — Boyd inspects repeat offenders aggressively.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Justin A. Boyd — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
